

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <u>Jones James</u>  (Last) (First) (Middle) 1600 WEST END AVENUE, SUITE 1300  (Street) NASHVILLE TN 37203  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>CUMBERLAND PHARMACEUTICALS INC [ CPIX ]</b>  3. Date of Earliest Transaction (Month/Day/Year) 10/02/2023  4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/02/2023		L	V	55 <sup>(1)</sup>	A	\$1.89	29,188	D	
Common Stock	10/03/2023		L	V	55 <sup>(1)</sup>	A	\$1.85	29,243	D	
Common Stock	10/04/2023		L	V	45 <sup>(1)</sup>	A	\$1.79	29,288	D	
Common Stock	10/05/2023		L	V	55 <sup>(1)</sup>	A	\$1.85	29,343	D	
Common Stock	10/06/2023		L	V	55 <sup>(1)</sup>	A	\$1.88	29,398	D	
Common Stock	10/09/2023		L	V	55 <sup>(1)</sup>	A	\$2.06	29,453	D	
Common Stock	10/10/2023		L	V	55 <sup>(1)</sup>	A	\$2.04	29,508	D	
Common Stock	10/11/2023		L	V	55 <sup>(1)</sup>	A	\$2.04	29,563	D	
Common Stock	10/12/2023		L	V	55 <sup>(1)</sup>	A	\$2.13	29,618	D	
Common Stock	10/13/2023		L	V	55 <sup>(1)</sup>	A	\$2.07	29,673	D	
Common Stock	10/16/2023		L	V	55 <sup>(1)</sup>	A	\$2.03	29,728	D	
Common Stock	10/17/2023		L	V	55 <sup>(1)</sup>	A	\$2.24	29,783	D	
Common Stock	10/18/2023		L	V	55 <sup>(1)</sup>	A	\$1.96	29,838	D	
Common Stock	10/19/2023		L	V	55 <sup>(1)</sup>	A	\$2.05	29,893	D	
Common Stock	10/20/2023		L	V	12 <sup>(1)</sup>	A	\$2.08	29,905	D	
Common Stock	10/23/2023		L	V	50 <sup>(1)</sup>	A	\$2.08	29,955	D	
Common Stock	10/24/2023		L	V	55 <sup>(1)</sup>	A	\$2.1	30,010	D	
Common Stock	10/25/2023		L	V	55 <sup>(1)</sup>	A	\$1.99	30,065	D	
Common Stock	10/26/2023		L	V	55 <sup>(1)</sup>	A	\$1.99	30,120	D	
Common Stock	10/27/2023		L	V	55 <sup>(1)</sup>	A	\$1.98	30,175	D	
Common Stock	10/30/2023		L	V	51 <sup>(1)</sup>	A	\$2.04	30,226	D	
Common Stock	10/31/2023		L	V	55 <sup>(1)</sup>	A	\$2.01	30,281	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

1. The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.

**Remarks:**

James Jones by /s/ John Hamm 11/03/2023  
as attorney-in-fact

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**